Addiction Rare in Patients Treated with Narcotics

Last updated

"Addiction Rare in Patients Treated with Narcotics" is the title of a letter to the editor written by Jane Porter and Hershel Jick and published in the January 10, 1980, issue of The New England Journal of Medicine . The letter analyzed data on patients who had been treated with opioids in a hospital setting, and concluded that addiction was uncommon among such patients. It has since been frequently misrepresented to claim that opioids are not addictive when prescribed for use at home, which has been blamed for contributing to the opioid epidemic in the United States.

Contents

Content

The letter reported on an examination of medical files of patients who had been hospitalized and treated with small doses of opioids. The authors concluded that of the 11,882 patients who received at least one narcotic drug, only four of them had developed a "reasonably well documented" addiction among patients who had no history of addiction. Its text read, in its entirety:

Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients who were monitored consecutively. Although there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The drugs implicated were meperidine in two patients, Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction. [1]

Influence

The article has been cited extensively as evidence that addiction was very rare among patients who were prescribed narcotics (more specifically, opioids). [2] [3] It became so well known that it is sometimes referred to simply as Porter and Jick. [4]

Methodological limitations

Methodological limitations from which the letter suffered included that the patients it reported on were all given opioids in small doses in a hospital. [2] [3] Additionally, in 2003, Jick told The New York Times that the study did not follow patients after they left the hospital. [5]

Misrepresentation

In 2017, the letter attracted renewed interest because the New England Journal of Medicine published a bibliographic analysis of the letter showing that it had been cited 608 times since it was published. In comparison, the other letters to the editor in the same issue of the Journal as Porter and Jick's letter had been cited a median of 11 times. [6] Of these 608 citations, the analysis also showed that 72.2% of them cited it in support of the claim that patients treated with opioids rarely developed addiction, and 80.8% did not mention that the letter only included data on prescriptions given to hospitalized patients. [7] It was also misrepresented in the popular media; a 1990 Scientific American article described it as an "extensive study," and a 2001 Time story dubbed it a "landmark study" showing that concerns about opioid addiction were "basically unwarranted." [8] In addition, Purdue Pharma, the manufacturer of OxyContin, trained its sales representatives to say that the risk of addiction among patients using the drug was less than 1 percent, citing Porter and Jick's letter as one of their sources. [9]

Role in the opioid epidemic

Because the letter has been frequently misrepresented to argue that opioids were rarely addictive, these misrepresentations have been blamed for contributing to the opioid epidemic. [3] [10] For example, a co-author of the 2017 bibliographic analysis, David Juurlink, has stated that he thinks the letter's appearance in a prestigious journal helped convince doctors that opioids were safe, saying, "I think it's fair to say that this letter went quite a long way." [11] Jick, who wrote the letter, has since said that "The letter wasn't of value to health and medicine in and of itself. So if I could take it back—if I knew then what I know now, I would never have published it. It wasn't worth it." [12]

Related Research Articles

<span class="mw-page-title-main">Oxycodone</span> Opioid medication

Oxycodone, sold under various brand names such as Roxicodone and OxyContin, is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin.

<span class="mw-page-title-main">Opioid</span> Psychoactive chemical

Opioids are a class of drugs that derive from, or mimic, natural substances found in the opium poppy plant. Opioids work in the brain to produce a variety of effects, including pain relief. As a class of substances, they act on opioid receptors to produce morphine-like effects.

Oxycodone/paracetamol, sold under the brand name Percocet among others, is a fixed-dose combination of the opioid oxycodone with paracetamol (acetaminophen), used to treat moderate to severe pain.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

<span class="mw-page-title-main">Buprenorphine</span> Opioid used to treat pain & opioid use disorder

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

<span class="mw-page-title-main">Sally Satel</span> American psychiatrist

Sally L. Satel is an American psychiatrist based in Washington, D.C. She is a lecturer at Yale University School of Medicine, a visiting professor of psychiatry at Columbia University, a senior fellow at the American Enterprise Institute, and an author.

A methadone clinic is a medical facility where medications for opioid use disorder (MOUD) are dispensed-—historically and most commonly methadone, although buprenorphine is also increasingly prescribed. Medically assisted drug therapy treatment is indicated in patients who are opioid-dependent or have a history of opioid dependence. Methadone is a schedule II (USA) opioid analgesic, that is also prescribed for pain management. It is a long-acting opioid that can delay the opioid withdrawal symptoms that patients experience from taking short-acting opioids, like heroin, and allow time for withdrawal management. In the United States, by law, patients must receive methadone under the supervision of a physician, and dispensed through an Opioid Treatment Program (OTP) certified by the Substance Abuse and Mental Health Services Administration and registered with the Drug Enforcement Administration.

<span class="mw-page-title-main">Purdue Pharma</span> American pharmaceutical company (1892–2019 bankruptcy)

Purdue Pharma L.P., formerly the Purdue Frederick Company (1892–2019), was an American privately held pharmaceutical company founded by John Purdue Gray. It was sold to Arthur, Mortimer, and Raymond Sackler in 1952, and then owned principally by the Sackler family and their descendants.

Raymond Sackler was an American physician and businessman. He acquired Purdue Pharma together with his brothers Arthur M. Sackler and Mortimer Sackler. Purdue Pharma is the developer of OxyContin, the drug at the center of the opioid epidemic in the United States.

<span class="mw-page-title-main">Woozle effect</span> False credibility due to quantity of citations

The Woozle effect, also known as evidence by citation, occurs when a source is widely cited for a claim it does not adequately support, giving said claim undeserved credibility. If results are not replicated and no one notices that a key claim was never well-supported in its original publication, faulty assumptions may affect further research.

<span class="mw-page-title-main">Opioid epidemic in the United States</span> Ongoing overuse of opioid medication in the US

In the United States, the opioid epidemic is an extensive, ongoing overuse of opioid medications, both from medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s, according to the Centers for Disease Control and Prevention (CDC), when opioids were increasingly prescribed for pain management, resulting in a rise in overall opioid use throughout subsequent years. The great majority of Americans who use prescription opioids do not believe that they are misusing them.

David Juurlink is a Canadian pharmacologist and internist. He is head of the Clinical Pharmacology and Toxicology division at Sunnybrook Health Sciences Centre in Toronto, Ontario, as well as a medical toxicologist at the Ontario Poison Centre and a scientist at the Institute for Clinical Evaluative Sciences. He is known for researching adverse effects caused by drug interactions, with some of this research funded by a New Investigator Award from the Canadian Institutes for Health Research. He has been very critical of his fellow physicians' regular prescribing of dangerous opioids like Tramadol and fentanyl. In June 2017, he published a letter analyzing citations to "Addiction Rare in Patients Treated with Narcotics", a 1980 letter in The New England Journal of Medicine that has often been cited to claim that opioids like OxyContin are rarely addictive.

Hershel M. Jick was an American medical researcher and associate professor of medicine at Boston University School of Medicine, where he was the director of the Boston Collaborative Drug Surveillance Program.

MedPage Today is a medical news-focused site owned by Ziff-Davis, LLC. It is based in New York City, and is geared primarily toward medical and health professionals.

<span class="mw-page-title-main">Richard Sackler</span> American billionaire (born 1945)

Richard Stephen Sackler is an American billionaire businessman and physician who was the chairman and president of Purdue Pharma, a former company best known as the developer of OxyContin, whose connection to the opioid epidemic in the United States was the subject of multiple lawsuits and fines, and that filed for bankruptcy in 2019. It has been claimed that Richard Sackler's Purdue is among ”the worst drug dealers in history” and the Sackler family have been described as the "most evil family in America". The company's downfall was the subject of the 2021 Hulu series Dopesick and the 2023 Netflix series Painkiller.

Massachusetts v. Purdue is a lawsuit filed on August 14, 2018, suing the Stamford, Connecticut-based company Purdue Pharma LP, which created and manufactures OxyContin, "one of the most widely used and prescribed opioid drugs on the market", and Purdue's owners, the Sacklers accusing them of "widespread fraud and deception in the marketing of opioids, and contributing to the opioid crisis, the nationwide epidemic that has killed thousands." Purdue denied the allegations.

<span class="mw-page-title-main">Opioid epidemic</span> Deaths due to abuse of opioid drugs

The opioid epidemic, also referred to as the opioid crisis, is the rapid increase in the overuse, misuse/abuse, and overdose deaths attributed either in part or in whole to the class of drugs called opiates/opioids since the 1990s. It includes the significant medical, social, psychological, demographic and economic consequences of the medical, non-medical, and recreational abuse of these medications.

<span class="mw-page-title-main">Timeline of the opioid epidemic</span>

The timeline of the opioid epidemic includes selected events related to the origins of Stamford, Connecticut-based Purdue Pharma, the Sackler family, the development and marketing of oxycodone, selected FDA activities related to the abuse and misuse of opioids, the recognition of the opioid epidemic, the social impact of the crisis, lawsuits against Purdue and the Sackler family.

Opioid agonist therapy (OAT) is a treatment in which prescribed opioid agonists are given to patients who live with Opioid use disorder (OUD). In the case of methadone maintenance treatment (MMT), methadone is used to treat dependence on heroin or other opioids, and is administered on an ongoing basis.

Curtis Wright IV is an American former government official known for his role in the Food and Drug Administration's approval of OxyContin for Purdue Pharma in 1995, followed by his subsequent employment by the company, which led to portrayals in films and reports in nonfiction books, magazines, and news media outlets of his alleged role as one of the key figures in the current opioid epidemic in the United States. Wright was implicated in a criminal conspiracy outlined in a 2006 United States Department of Justice review document that was first made public in Purdue Pharma's 2019 bankruptcy proceedings. Although that case was settled in a 2007 plea agreement deal, members of United States Congress have requested the full 2006 documentation from the Department of Justice with the goal of opening a new case based upon the evidence then gathered. Parts of Wright's sworn depositions in 2003 and 2018 have internal contradictions and differ from documentary evidence described the 2003–2006 U.S. Federal Government investigation into Purdue Pharma.

References

  1. ↑ Porter, J.; Jick, H. (10 January 1980). "Addiction Rare in Patients Treated with Narcotics". New England Journal of Medicine. 302 (2): 123. doi: 10.1056/NEJM198001103020221 . PMID   7350425.
  2. 1 2 Jacobs, Harrison (26 May 2016). "This one-paragraph letter may have launched the opioid epidemic". Business Insider. Retrieved 24 June 2017.
  3. 1 2 3 Kounang, Nadia (1 June 2017). "One short letter's huge impact on the opioid epidemic". CNN. Retrieved 24 June 2017.
  4. ↑ Hawkins, Derek (2 June 2017). "How a short letter in a prestigious journal contributed to the opioid crisis". The Washington Post. Retrieved 24 June 2017.
  5. ↑ Meier, Barry (25 November 2003). "The Delicate Balance Of Pain and Addiction". The New York Times. Retrieved 24 June 2017.
  6. ↑ Kaplan, Karen (31 May 2017). "How a 5-sentence letter helped fuel the opioid addiction crisis". Los Angeles Times. Retrieved 25 June 2017.
  7. ↑ Leung, Pamela T.M.; Macdonald, Erin M.; Stanbrook, Matthew B.; Dhalla, Irfan A.; Juurlink, David N. (June 2017). "A 1980 Letter on the Risk of Opioid Addiction". New England Journal of Medicine. 376 (22): 2194–2195. doi: 10.1056/NEJMc1700150 . PMID   28564561.
  8. ↑ Zhang, Sarah (2 June 2017). "The One-Paragraph Letter From 1980 That Fueled the Opioid Crisis". The Atlantic. Retrieved 24 June 2017.
  9. ↑ Van Zee, Art (February 2009). "The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy". American Journal of Public Health. 99 (2): 221–227. doi:10.2105/AJPH.2007.131714. PMC   2622774 . PMID   18799767.
  10. ↑ Engber, Daniel (11 June 2017). "Bad Footnotes Can Be Deadly". Slate. Retrieved 24 June 2017.
  11. ↑ "Opioid crisis: The letter that started it all". BBC News. 3 June 2017. Retrieved 24 June 2017.
  12. ↑ Haney, Taylor (16 June 2017). "Doctor Who Wrote 1980 Letter On Painkillers Regrets That It Fed The Opioid Crisis". NPR. Retrieved 24 June 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.